Introduction
For more than 50 years, anterior cervical discectomy and fusion (ACDF) has been the workhorse procedure for cervical degenerative pathology. (Bailey & Badgely, 1960; Cloward, 1961; Robinson & Smith, 1955) The procedure has yielded successful results clinically in multiple large series. (Bohlman et al, 1993; Gore & Sepic, 1984) Advances in allograft and cage techniques as well as the use of anterior plating systems have diminished complications in ACDF. However, concerns about adjacent segment degeneration (ASD) have tempered some enthusiasm for the procedure. Gore et al (Gore & Sepic, 1998 ) reviewed a series of 50 ACDF patients followed long term. Almost universally, the patients developed ASD. One-third of the cohort developed recurrent pain with half of the symptomatic group requiring additional surgery. Hilibrand et al (Hilibrand et al, 1999 ) evaluated a group of 374 patients undergoing ACDF. They showed a 2.9% per year risk of development of symptomatic ASD, with two thirds of the symptomatic patients requiring additional surgery. Goffin et al (Goffin et al, 1995) prospectively followed a series of ACDF patients who underwent the procedure for either a degenerative or traumatic condition. Follow-up was for five to nine years. Sixty percent of the patients developed ASD, equally distributed between the older degenerative population and the younger traumatic population, providing evidence that fusion may accelerate degenerative changes. Goffin et al (Goffin et al, 2004 ) reviewed a larger series of ACDF patients followed for an average of 8.3 years. In this group, 92% of the patients developed ASD, though they had a much lower rate of additional surgical procedures, 6.1% for the entire length of follow-up, distinctly lower than Hilibrand et al. Numerous cadaveric biomechanical studies (Eck et al, 2002; Pospiech et al, 1999) evaluating adjacent level intradiscal pressures and range of motion in simulated fusion models have shown that both increase after fusion. These altered biomechanics may thus accelerate ASD. Against this background, centers began experimenting with cervical disc arthroplasty in the 1980s. Cummins and collaborators at the Frenchay Hospital, Bristol, England developed a metal-on-metal ball and socket arthroplasty and implanted it on a small series of patients in the 1990s. (Cummins et al, 1998) The arthroplasty underwent a number of design changes and is now known as Prestige. Bryan, in the US, developed a one piece metal-on-polymer device called the Bryan Cervical Disc Replacement, initially evaluated clinically in Europe. (Goffin et al, 2002) ProDisc-C arthroplasty is a metal-on-polyethylene implant adopted from the ProDisc-L lumbar disc arthroplasty developed by Thierry Marnay. (Delamarter & Pradhan, 2004 ) Since www.intechopen.com Recent Advances in Arthroplasty 500 these first three devices have been developed, the number of cervical disc arthroplasties has proliferated. The literature in this nascent field is limited, but growing each year.
Types of cervical disc arthroplasty
It is beyond the scope of this chapter to catalogue all of the cervical disc arthroplasties available; the devices with the most clinical experience will be discussed.
Prestige
The technology from the early designs of Cummins et al was acquired by Medtronic Sofamor Danek (Memphis, Tennessee) and rebadged Prestige. With Prestige I, the initial ball and socket design which was entirely fabricated from stainless steel, was converted to a ball and trough design, allowing limited translation. The anterior flanges were diminished in size and a locking screw added to prevent bone screw backout. Prestige II was further modified by again reducing the anterior flange and modifying the endplates to allow bone ingrowth. Prestige ST was the design evaluated in the United States as part of the Food and Drug Administration (FDA) investigational device evaluational (IDE) study. This arthroplasty incorporates the features of Prestige II with further shortened anterior flanges. The final design is Prestige LP, a major change from its predecessors. Instead of stainless steel, the Prestige LP is made from a titanium ceramic composite, preserving the ball and trough bearing design. It has a titanium plasma spray on the endplates for bone ingrowth, as well as two pairs of rails allowing immediate fixation. The flange and locking bone screws have been removed. The Prestige LP, being made of titanium, has a better compatibility than stainless steel in MRI imaging. (Figure 1 
Porous-Coated Motion (PCM) Cervical Arthroplasty
The Porous-Coated Motion (PCM) Cervical Arthroplasty (Cervitech, Rockaway, New Jersey) consists of two cobalt-chrome-molybdenum (CoCrMo) endplates that have a titanium calcium phosphate porous coated backing for bone ingrowth. The device is inserted by a "press-fit" method, but the endplates have transverse serrated rows of teeth that resist migration. The bearing surface is an ultra high molecular weight polyethylene (UHMWPE) convex insert of large radius of curvature attached to the inferior endplate which articulates with the polished CoCrMo concave surface of the superior endplate. 
Clinical results
As a result of the US FDA IDE studies, there have been a number of thorough clinical evaluations of cervical disc arthroplasty. These trials have been designed as non-inferiority studies, comparing cervical disc arthroplasty to ACDF. The Prestige ST results at two years follow-up were reported by Mummaneni et al. (Mummaneni et al, 2007) The study, similar to all of the FDA IDE studies, was a prospective, randomized, multicenter trial comparing Prestige ST cervical disc arthroplasty to ACDF for one level pathology. Five hundred fortyone patients were enrolled with 1:1 randomization; over 75% of patients were available for two-year follow-up. There were no statistically significant differences in the revision surgeries at the index level (3.4% ACDF, 1.9% Prestige ST). However, the rate of surgery at adjacent levels was statistically higher for ACDF (3.4% versus 1.1%, p=0.0492). Neurological success, defined as maintenance or improvement in the neurological exam, was better with Prestige ST (92.8%) than ACDF (84.3%). Clinically, the patients were evaluated by Shortform 36 (SF-36), Visual Analogue Scale (VAS) and the Neck Disability Index (NDI). While both groups improved significantly from the preoperative state, there was no statistically significant difference between the groups at final follow-up. Overall success was defined as an NDI improvement ≥ 15 points, maintenance of the neurological status and the absence of implant-related adverse events. The arthroplasty group showed overall success in 79.3% of the patients compared to 67.8% in the ACDF group. As a sidebar, the Prestige ST patients were able to return to work on average at 45 days postoperatively, compared to 61 days for the ACDF patients.
A small prospective study compared results for Prestige LP and ACDF at a minimum of two years follow-up. Single and multilevel procedures were evaluated by VAS, NDI, SF-36 and Japanese Orthopedic Association scores. Clinically, while both groups improved significantly, there was no statistical difference between them. Motion was preserved in the Prestige LP group at a mean of 13.9° on flexion/extension lateral radiographs of two years. In all the clinical studies evaluating cervical disc arthroplasty and HO, there has been no correlation between the development of HO and the clinical results. Barbargallo et al (Barbargallo et al, 2010 ) specifically looked at this aspect of cervical disc arthroplasty. They found an overall rate of HO development of 42% and no difference in the functional scores in patients with or without HO. Segmental range of motion of ≥ 3° was preserved in 93.8% of patients with HO.
Radiographic results

Complications
All of the large clinical series published on cervical disc arthroplasty have not reported any severe neurological injuries, such as quadriplegia. The rate of revision surgery at the index level has been acceptably low. None of the cervical disc arthroplasty series have had implants removed for infection. Concerns of wear debris and local and remote inflammatory changes in cervical disc arthroplasty have been expressed. In vitro wear tests have been submitted to the United States FDA as part of the clinical approval process. Generally, wear debris volume has been in the range of 10% of that produced by large joint arthroplasties. Anderson et al (Anderson et al 2004) published in vitro wear testing on the Bryan Cervical Disc Replacement using a custom cervical spine simulator on six disc assemblies. At 10 million cycles, the mean mass loss was 1.76% and a mean height loss of 0.75%. At 40 million cycles there was an 18% mass loss. Wear particles were elliptical in shape and larger than typical particles in large joint arthroplasties. Anderson studied local and remote wear debris and the subsequent inflammatory response using an in vivo caprine model with implanted Bryan arthroplasties. Sacrificed animals at up to twelve months showed an increase in extracellular wear debris. No apparent inflammatory response was seen locally or distally in these animals. Clinically, there have been scattered case reports of osteolysis after cervical disc arthroplasty implantation. Tumialan and Gluf reported on a 30-year-old man who underwent a ProDisc-C arthroplasty at C5-6. (Tumialan & Gluf, 2011) He had an uneventful postoperative course until he developed worsening neck pain at nine months. Repeat imaging studies by 15 months showed a progressive osteolysis process in the vicinity of the superior endplate and keel. Work-up for infection was negative. The patient underwent explantation of the arthroplasty and conversion to a fusion. The implant was studied after removal and no defects or unusual wear was noted. The authors hypothesized that the most likely cause of the osteolysis was an immune mediated process. Longer study periods are needed to determine the significance of wear changes and the rate of osteolysis of cervical disc arthroplasty.
Conclusions
Cervical disc arthroplasty has been one of the most closely scrutinized surgical procedures in the last decade. Short-term prospective clinical studies show cervical disc arthroplasty to be at least the equivalent of ACDF for degenerative pathology. There is some evidence that cervical disc arthroplasty may play a role in diminishing adjacent segment disease. However, the long-term efficacy and safety of cervical disc arthroplasty await further clinical studies.
